INMED TO PRESENT AT CANACCORD GENUITY CONFERENCE

INMED TO PRESENT AT CANACCORD GENUITY CONFERENCE
INMED TO PRESENT AT CANACCORD GENUITY CONFERENCE
by is licensed under

InMed Pharmaceuticals, Inc. (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today it will present at Canaccord Genuity's 2nd Annual Cannabis Investor Day taking place at The Fairmont Waterfront Hotel in Vancouver, BC, on Wednesday, January 24, 2018.

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

Read original releasehttps://www.inmedpharma.com/news-media/news/2018/inmed-to-present-at-canaccord-genuity-conference/
Read More
Tags
Cannabis News, InMed, Investing News
Thumbnail Photo Credit: by is licensed under